for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

argenx SE

ARGX.BR

Latest Trade

122.30EUR

Change

2.40(+2.00%)

Volume

31,692

Today's Range

121.00

 - 

124.80

52 Week Range

93.05

 - 

154.00

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Latest Developments

Argenx FY Operating Loss Widens To 178.6 Million Euros

Feb 27 (Reuters) - argenx SE <ARGX.BR>::ARGENX REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES FOURTH QUARTER BUSINESS UPDATE.TOPLINE DATA FROM PHASE 3 ADAPT TRIAL OF EFGARTIGIMOD IN GMG EXPECTED IN MID-2020.CONTINUED PROGRESS ACROSS BROADEST FCRN ANTAGONIST PIPELINE WITH UP TO FIVE PHASE 3 TRIALS TO BE ONGOING IN 2020.ENDED 2019 WELL-CAPITALIZED TO ADVANCE LATE-STAGE PIPELINE WITH EUR 1.3 BILLION IN CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS.TOTAL COMPREHENSIVE LOSS FOR YEAR ENDED DECEMBER 31, 2019 WAS EUR 163.0 MILLION COMPARED TO EUR 66.6 MILLION FOR YEAR ENDED DECEMBER 31, 2018..FOR THE YEAR ENDED DECEMBER 31, 2019, FINANCIAL INCOME AMOUNTED TO €14.4 MILLION COMPARED TO €3.7 MILLION FOR THE YEAR ENDED DECEMBER 31, 2018.OPERATING INCOME INCREASED BY €53.4 MILLION FOR THE YEAR ENDED DECEMBER 31, 2019 TO €82.6 MILLION, COMPARED TO €29.2 MILLION FOR THE YEAR ENDED DECEMBER 31, 2018.CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS TOTALED €1,335.8 MILLION FOR THE YEAR ENDED DECEMBER 31, 2019.FY REVENUE EUR 69.8 MILLION VERSUS EUR 21.5 MILLION YEAR AGO.

Argenx Confirms 2021 Vision

Jan 9 (Reuters) - argenx SE <ARGX.BR>::ENROLLMENT COMPLETE IN PHASE 3 ADAPT TRIAL OF EFGARTIGIMOD IN GMG; TOPLINE DATA EXPECTED MID-2020.CONTINUES TO EXECUTE ON ITS PLAN TO BECOME A FULLY INTEGRATED IMMUNOLOGY COMPANY THROUGH ITS 'ARGENX 2021' VISION.ON TRACK TO LAUNCH FIRST FCRN ANTAGONIST WITH EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS (GMG) IN 2021.PHASE 3 ADAPT TRIAL DESIGN TO BE DISCUSSED DURING 38TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.WE’RE ANNOUNCING TODAY POSITIVE PROOF-OF-CONCEPT DATA FOR EFGARTIGIMOD IN PV, OUR THIRD ‘BEACHHEAD’ INDICATION.POSITIVE PHASE 2 DATA OF EFGARTIGIMOD IN PV SUPPORT ADVANCEMENT TO REGISTRATIONAL TRIAL.

Argenx Announces Efgartigimod Phase 2 Trial Results

Dec 11 (Reuters) - ARGENX SE <ARGX.BR>::ANNOUNCED ON TUESDAY RESULTS FROM THE COMPLETED PHASE 2 CLINICAL TRIAL OF ITS FCRN ANTAGONIST, EFGARTIGIMOD.EFGARTIGIMOD WAS WELL-TOLERATED AND SHOWED A CORRELATION OF REDUCED IGG LEVELS, INCREASED PLATELET COUNTS AND REDUCED BLEEDING IN ITP PATIENTS.EFGARTIGIMOD HAS DEMONSTRATED A FAVORABLE TOLERABILITY PROFILE AND THE ABILITY TO DRIVE ENCOURAGING RESPONSE RATES - CMO.PHASE 3 PROGRAM OF EFGARTIGIMOD IN ITP ON TRACK TO INITIATE THIS MONTH.PHASE 3 ADAPT TRIAL OF IV EFGARTIGIMOD IS ONGOING IN GMG WITH DATA EXPECTED IN H2 2020.PHASE 2 PROOF-OF-CONCEPT TRIAL OF IV EFGARTIGIMOD IS ONGOING IN PV AND DATA ARE EXPECTED IN H1 2020.PHASE 2 PROOF-OF-CONCEPT TRIAL OF SC EFGARTIGIMOD IN CIDP IS EXPECTED TO START BEFORE THE END OF 2019.

Argenx Receives First Milestone Payment Under Janssen Collaboration

Dec 9(Reuters) - ARGENX SE <ARGX.BR>::ARGENX ANNOUNCED ON SATURDAY RECEIPT OF FIRST MILESTONE PAYMENT UNDER JANSSEN COLLABORATION AND PROVIDES DATA UPDATE FROM PHASE 1 DOSE ESCALATION TRIAL OF CUSATUZUMAB IN ACUTE MYELOID LEUKEMIA AT ASH ANNUAL MEETING.COMPANY WILL RECEIVE FIRST DEVELOPMENT MILESTONE PAYMENT OF $25 MILLION FROM GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH CILAG GMBH INTERNATIONAL, AFFILIATE OF JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON.KEY HIGHLIGHTS FROM ASH: 100% OF PATIENTS ACHIEVED RESPONSE INCLUDING EIGHT WITH COMPLETE RESPONSE (CR), TWO WITH COMPLETE RESPONSE WITH INCOMPLETE HEMATOLOGIC RECOVERY (CRI), AND TWO WITH PARTIAL RESPONSE (PR); 83% OF PATIENTS ACHIEVED EITHER A CR OR CRI.KEY HIGHLIGHTS FROM ASH: OF NINE CR/CRI PATIENTS EVALUABLE FOR MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY, FOUR ACHIEVED MRD NEGATIVITY USING THRESHOLD OF 10-3 WHICH IS CONSISTENT WITH PREVIOUS DATA CUT-OFF IN OCTOBER 2018.KEY HIGHLIGHTS FROM ASH: FOUR PATIENTS HAVE REMAINED IN STUDY FOR AT LEAST 12 MONTHS.KEY HIGHLIGHTS FROM ASH: THREE PATIENTS FROM STUDY HAVE BEEN RE-CLASSIFIED WITH RISK CATEGORY BASED ON NEW MUTATION INFORMATION OR REASSESSMENT OF EXISTING MUTATION INFORMATION.CUSATUZUMAB CONTINUED TO BE WELL-TOLERATED IN PATIENTS WITH AML ACROSS THE DIFFERENT DOSES.

Argenx: Additional ADSs Purchase Brings Proceeds To Around $557 Mln From Global Offering

Nov 8 (Reuters) - Argenx Se <ARGX.BR>::ARGENX ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL ADSS.THIS OPTION EXERCISE BRINGS ANTICIPATED TOTAL GROSS PROCEEDS FROM GLOBAL OFFERING TO APPROXIMATELY $557 MILLION FROM SALE OF AN AGGREGATE OF 4,600,000 ORDINARY SHARES.THIS OPTION EXERCISE BRINGS ANTICIPATED TOTAL GROSS PROCEEDS FROM GLOBAL OFFERING TO APPROXIMATELY $557 MILLION (APPROXIMATELY EUR 502 MILLION).MORGAN STANLEY, COWEN, BOFA SECURITIES AND EVERCORE ACTED AS JOINT BOOKRUNNING MANAGERS FOR OFFERING.KEMPEN ACTED AS LEAD MANAGER FOR OFFERING AND WOLFE CAPITAL MARKETS AND ADVISORY ACTED AS CO-MANAGER.

Argenx 9-Month Operating Income Up At 61.2 Million Euros

Oct 24 (Reuters) - ARGENX SE <ARGX.BR>::EXPECTS ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND PLANNED OPEX, CAPEX REQUIREMENTS UP TO EXPECTED 2021 LAUNCH OF EFGARTIGIMOD IN GMG.CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS TOTALED EUR 923.2 MILLION ON SEPT 30.TOTAL OPERATING INCOME EUR 61.2 MILLION FOR NINE MONTHS.9-MONTH REVENUE EUR 52.3 MILLION VERSUS EUR 19.9 MILLION.TOTAL COMPREHENSIVE LOSS FOR NINE MONTHS WAS EUR 70.1 MILLION.EXPECTS TO FILE FORMAL PROTEST LETTER AGAINST BELGIAN TAX AUTHORITY TAX ASSESSMENT FROM AUG.PHASE 3 ADAPT TRIAL OF EFGARTIGIMOD IN GMG PATIENTS TOPLINE RESULTS EXPECTED IN 2H20.EXPECTS OPEX, CAPEX REQUIREMENTS TO CONTINUE TO INCREASE YEAR-OVER-YEAR.TWO EFGARTIGIMOD TRIAL INITIATIONS EXPECTED IN 4Q19.DATA FROM PHASE 1 HV TRIAL OF ENHANZE SC FORMULATION OF EFGARTIGIMOD EXPECTED BY YE19.

Argenx H1 Operating Loss Widens to 54.5 Million

Aug 1 (Reuters) - ARGENX SE <ARGX.BR>::ARGENX REPORTS HALF YEAR 2019 FINANCIAL RESULTS AND SECOND QUARTER BUSINESS UPDATE.H1 LOSS FOR THE PERIOD AND TOTAL COMPREHENSIVE LOSS EUR 45.1 MILLION VERSUS LOSS OF EUR 20.1 MILLION YEAR AGO.H1 TOTAL OPERATING INCOME EUR 51.3 MILLION VERSUS EUR 20.5 MILLION YEAR AGO.H1 REVENUE EUR 43.5 MILLION VERSUS EUR 17.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR 54.5 MILLION VERSUS LOSS OF EUR 25.4 MILLION YEAR AGO.ON JUNE 30, 2019, CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS TOTALED €944.3 MILLION, COMPARED TO €564.6 MILLION ON DECEMBER 31, 2018.EXPECTS THAT ITS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND PLANNED OPERATING AND CAPITAL EXPENSE REQUIREMENTS INTO 2021.EXPECTS OPERATING AND CAPITAL EXPENSE REQUIREMENTS TO CONTINUE TO INCREASE YEAR-OVER-YEAR.

Argenx Plans To Launch A Phase 2 Trial In CIDP Before End Of 2019

May 28 (Reuters) - ARGENX SE <ARGX.BR>::IS PLANNING TO LAUNCH A PHASE 2 PROOF-OF-CONCEPT TRIAL IN CIDP BEFORE END OF 2019.PHASE 2 PROOF-OF-CONCEPT TRIAL OF IV EFGARTIGIMOD IS ONGOING IN PV AND DATA ARE EXPECTED IN 2020.SECOND PHASE 3 PROGRAM OF EFGARTIGIMOD IS EXPECTED TO LAUNCH THIS YEAR IN ITP.

Argenx Announces Pipeline Expansion And “Argenx 2021” Vision

May 22 (Reuters) - ARGENX SE <ARGX.BR>::ARGENX ANNOUNCES PIPELINE EXPANSION AND “ARGENX 2021” VISION TO BUILD INTEGRATED IMMUNOLOGY COMPANY AT 2019 RESEARCH AND DEVELOPMENT DAY.EXPANDS PIPELINE WITH ARGX-117 AND ARGX-118; TWO NEW PIPELINE CANDIDATES FROM ITS INNOVATIVE ACCESS PROGRAM ADDRESSING FIRST-IN-CLASS TARGETS.A FIRST PHASE 2 REGISTRATION-DIRECTED TRIAL IN ACUTE MYELOID LEUKEMIA (AML) IS EXPECTED TO START IN SECOND HALF OF 2019.TODAY, ARGENX WILL ALSO BRING FORWARD ITS "ARGENX 2021" VISION.BY END OF 2021, ARGENX EXPECTS TO LAUNCH EFGARTIGIMOD IN U.S. IN ITS FIRST INDICATION GMG, IF APPROVED..ARGX-117 FIRST-IN-HUMAN CLINICAL STUDIES ARE EXPECTED TO START IN Q1 OF 2020.ITS PARTNER JANSSEN INTENDS TO INITIATE IN SECOND HALF OF 2019 ITS FIRST PHASE 2 AND REGISTRATION-DIRECTED CLINICAL TRIAL OF CUSATUZUMAB.PHASE 2 OF CUSATUZUMAB EXPECTED TO ENROLL UP TO 150 PATIENTS.PHASE 2 OF CUSATUZUMAB TWO-PART TRIAL.

Argenx Q1 Total Operating Income Up At 40.0 Million Euros

May 9 (Reuters) - ARGENX SE <ARGX.BR>::Q1 TOTAL OPERATING INCOME EUR 40.0 MILLION VERSUS EUR 6.9 MILLION YEAR AGO.Q1 TOTAL COMPREHENSIVE PROFIT EUR 6.7 MILLION VERSUS LOSS OF EUR 17.7 MILLION YEAR AGO.CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS TOTALED €961.6 MILLION ON MARCH 31, 2019, COMPARED TO €564.6 MILLION ON DECEMBER 31, 2018.PHASE 3 ADAPT CLINICAL TRIAL, INCLUDING ONE-YEAR OPEN-LABEL EXTENSION STUDY, IS ONGOING FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS WITH TOPLINE DATA EXPECTED IN 2020.Q1 REVENUE EUR 36.5 MILLION VERSUS EUR 5.6 MILLION YEAR AGO.PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL ONGOING FOR TREATMENT OF PEMPHIGUS VULGARIS; DATA EXPECTED IN 2020.PHASE 2 CLINICAL TRIAL FOR TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY EXPECTED TO START IN SECOND HALF OF 2019.PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS PLANNED WITH ENHANZE SC FORMULATION OF EFGARTIGIMOD AS PART OF COLLABORATION WITH HALOZYME ANNOUNCED IN FEBRUARY 2019.FOR THE THREE MONTHS ENDED MARCH 31, 2019, FINANCIAL INCOME AMOUNTED TO €3.5 MILLION VERSUS €0.5 MILLION LAST YEAR.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up